[go: up one dir, main page]

WO2000027340A3 - USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF - Google Patents

USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF Download PDF

Info

Publication number
WO2000027340A3
WO2000027340A3 PCT/US1999/026696 US9926696W WO0027340A3 WO 2000027340 A3 WO2000027340 A3 WO 2000027340A3 US 9926696 W US9926696 W US 9926696W WO 0027340 A3 WO0027340 A3 WO 0027340A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
fragments
compositions
inhibiting angiogenesis
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/026696
Other languages
French (fr)
Other versions
WO2000027340A2 (en
WO2000027340A9 (en
Inventor
Yuen Shing
Hui Zhao
Krzystof Bojanowski
M Judah Folkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to AU20234/00A priority Critical patent/AU2023400A/en
Publication of WO2000027340A2 publication Critical patent/WO2000027340A2/en
Publication of WO2000027340A3 publication Critical patent/WO2000027340A3/en
Publication of WO2000027340A9 publication Critical patent/WO2000027340A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A therapeutic composition comprising an angiogenesis-inhibiting amount of a transfer ribonucleic acid (tRNA) or a fragment of tRNA and a pharmaceutically acceptable excipient are provided. Methods of administering the composition to inhibit an angiogenesis-dependent disease, such as cancer, are also provided.
PCT/US1999/026696 1998-11-12 1999-11-12 USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF Ceased WO2000027340A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20234/00A AU2023400A (en) 1998-11-12 1999-11-12 Compositions and methods for inhibiting angiogenesis using trna and fragments thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10803698P 1998-11-12 1998-11-12
US60/108,036 1998-11-12

Publications (3)

Publication Number Publication Date
WO2000027340A2 WO2000027340A2 (en) 2000-05-18
WO2000027340A3 true WO2000027340A3 (en) 2000-08-17
WO2000027340A9 WO2000027340A9 (en) 2000-11-30

Family

ID=22319903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026696 Ceased WO2000027340A2 (en) 1998-11-12 1999-11-12 USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF

Country Status (2)

Country Link
AU (1) AU2023400A (en)
WO (1) WO2000027340A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
PL2578685T3 (en) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3590949T1 (en) 2010-10-01 2022-09-30 Modernatx, Inc. Ribonucleic acids containing N1-methyl-pseudouracil and their uses
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2649364C2 (en) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Modified nucleoside, nucleotide and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
SI2922554T1 (en) 2012-11-26 2022-06-30 Modernatx, Inc. Terminally modified rna
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (en) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 Polynucleotides encoding low density lipoprotein receptor
US10662480B2 (en) 2014-02-04 2020-05-26 Thomas Jefferson University Specific expression of half-tRNA in cancers
WO2018119421A1 (en) * 2016-12-22 2018-06-28 Thomas Jefferson University Compositions and methods of using rna fragments
KR20230026992A (en) 2020-04-14 2023-02-27 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 TREM compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE876739A (en) * 1978-06-03 1979-12-03 Boehringer Sohn Ingelheim PREPARATIONS BASED ON RIBONUCLEIC TRANSFER ACIDS, WITH ANTIVIRAL ACTIVITY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE876739A (en) * 1978-06-03 1979-12-03 Boehringer Sohn Ingelheim PREPARATIONS BASED ON RIBONUCLEIC TRANSFER ACIDS, WITH ANTIVIRAL ACTIVITY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HWANG J.-M. ET AL: "Optic neuropathy associated with mitochondrial tRNA (Leu(UUR)) A3243G mutation.", OPHTHALMIC GENETICS, (1997) 18/2 (101-105)., XP000901440 *
SMITH P R (REPRINT) ET AL: "Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA (Leu) A to G mutation", OPHTHALMOLOGY, (JUN 1999) VOL. 106, NO. 6, PP. 1101-1108. PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS, 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106. ISSN: 0161-6420., QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND (Reprint);UNIV BIRMINGHAM, DEPT MED, BIRMINGHAM, W MIDLANDS, ENGLAND; BIRMINGHAM & MIDLAND EYE HOSP, CITY HOSP NHS TRUST, BIRMIN, XP000901445 *
SUK, D. ET AL: "Toxicological and antiproliferative effects of N6-(.DELTA.2- isopentenyl)adenosine, a natural component of mammalian transfer RNA", CANCER RES. (1970), 30(5), 1429-36, XP000901623 *
ZHAO, HUI ET AL: "New role for tRNA and its fragment purified from human urinary bladder carcinoma conditioned medium: Inhibition of endothelial cell growth.", JOURNAL OF CELLULAR BIOCHEMISTRY, (NOV., 1999) VOL. 76, NO. 1, PP. 109-117., XP002135747 *

Also Published As

Publication number Publication date
WO2000027340A2 (en) 2000-05-18
WO2000027340A9 (en) 2000-11-30
AU2023400A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
WO2000027340A3 (en) USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF
WO2002042295A3 (en) Peptides as met-ap2 inhibitors
IL155283A0 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2000056296A3 (en) Compositions for improving fertility
EP1024145A3 (en) Novel azalides and methods of making same
WO2002080965A3 (en) Vaccine composition
WO2000066528A3 (en) Quinones for treatment of diseases
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
AU3850600A (en) Dalda analogs and their use
WO2001045678A3 (en) Medicament, a method for its production and the use thereof
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2001076638A3 (en) Compositions for drug delivery
WO2001051044A3 (en) Substances for use in treating psoriasis
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
WO2003092608A3 (en) Methionine aminopeptidase-2 inhibitors and methods of use thereof
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
WO2002022145A3 (en) Components of canola for the treatment of cancer
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP0104002A3 (en) Alpha2-antagonists tricyclic delta3-piperidines, process for their producing the pharmaceutical compositions containing them and their use as medicament
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2003077874A3 (en) Substituted tetrahydroisoquinoline compounds, methods of making, and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase